The weight loss drug market is projected to surpass $100 billion in annual revenue by 2030, eclipsing even the peak sales of COVID vaccines. Major players like Novo Nordisk and Eli Lilly are reshaping the landscape, with Eli Lilly expanding its manufacturing capabilities to meet soaring demand. The rapid evolution of this industry highlights a significant shift from small biotech firms to dominant pharmaceutical giants, marking the beginning of a new era in weight management treatments.
